Advertisement

Intratype variants of the E2 protein from human papillomavirus type 18 induce different gene expression profiles associated with apoptosis and cell proliferation

  • Alma Mariana Fuentes-González
  • J. Omar Muñoz-Bello
  • Joaquín Manzo-Merino
  • Adriana Contreras-Paredes
  • Abraham Pedroza-Torres
  • Jorge Fernández-Retana
  • Carlos Pérez-Plasencia
  • Marcela LizanoEmail author
Original Article
  • 145 Downloads

Abstract

Persistent infections with high-risk human papillomaviruses (HR-HPVs) are linked to the development of cervical cancer due to a deregulation of the productive viral cycle in the host cell, leading to cell transformation. The E2 viral protein is expressed early during an HPV infection and regulates viral replication and transcription. Other functions have been attributed to E2, such as the promotion of apoptosis that are independent of its role in the regulation of the expression of E6 and E7 viral oncogenes. Moreover, it has been shown that the HPV16 E2 protein has regulatory effects on cellular gene expression, suggesting that it participates in the modulation of different cellular processes. Intratype genomic variations within high-risk HPV types have an impact on the prognosis of HPV-related lesions. Nevertheless, the biological significance of HPV18 E2 intratype variations has not been analysed previously. The aim of this study was to determine whether HPV18 E2 intratype variations differentially modulate gene expression and whether cell-death-related genes are affected by variations in E2. We demonstrate that HPV18 E2 intratype Asian Amerindian (AsAi) and African (Af) variants differentially affect gene expression profiles. Although the E2-AsAi variant was found to modulate a larger number of cellular genes, both E2 variants affected similar cellular processes. Nevertheless, E2-AsAi and E2-Af variants showed differences in their ability to induce apoptosis, where E2-Af had a stronger effect. The differences in gene expression profiles in cells harbouring E2 intratype variants suggest a possible effect on diverse cellular signalling pathways, and this might suggest an approach for identifying biological processes regulated by HPV18 E2 intratype variants.

Abbreviations

HPV

Human papillomavirus

HR

High-risk

CC

Cervical cancer

DMEM

Dulbecco´s modified Eagle´s medium

RT-qPCR

Quantitative reverse transcription PCR

ΔΔ Ct

Double delta Ct

Notes

Acknowledgements

Alma Mariana Fuentes-González is a Ph.D. student from Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and received a scholarship from CONACyT (268404). We thank María Alexandra Rodríguez-Sastre and Patricia de la Torre from Instituto de Investigaciones Biomédicas, UNAM for technical assistance.

Author contributions

All of the authors listed made substantial contributions to the manuscript and qualify for authorship, and no authors have been omitted. Conception and design, ML; development of methodology and acquisition of data, AMFG, JOMB, JFR and JMM; analysis and interpretation of data, AMFG, JMM, JOMB, ML, APT, CPP; writing and revision of the manuscript, AMFG, JMM, ML, JOMB and ACP. All the authors read and approved the final manuscript.

Funding

This work was partially supported by CONACYT México grant CB-166808 and INCan Ref. 005/017/IBI.

Compliance with ethical standards

Conflict of interest

There are no commercial or financial conflicts of interest to declare.

Supplementary material

705_2018_4124_MOESM1_ESM.jpg (101 kb)
Figure S1. Nucleotide and amino acid changes between HPV18 E2 intratype variants. Differences of nucleotide and amino acid positions within HPV18 E2-AsAi and HPV18 E2-Af are shown. Del: deleted nucleotide (JPEG 100 kb)
705_2018_4124_MOESM2_ESM.jpg (998 kb)
Figure S2. Cell death and DNA damage response genes regulated by HPV18 E2-AsAi and E2-Af. A) HPV18 E2-AsAi and B) HPV18 E2-Af regulate the expression of genes associated to cell death and DNA damage response illustrated by the Ingenuity Pathway Analysis Tool. Up-regulated genes are shown in red and down-regulated genes are depicted in blue (JPEG 998 kb)
705_2018_4124_MOESM3_ESM.docx (16 kb)
Supplementary Table S1. Sequences of primers used for RT-qPCR assay. 18S, FOSB, EPS15, CASP4, EPHA2, RAB4B, TRAF1, and HPV18 E2 primers were used to validate the expression of the selected genes (DOCX 15 kb)
705_2018_4124_MOESM4_ESM.xlsx (90 kb)
Supplementary Table S2. Genes modulated by the HPV18 E2-AsAi variant. After normalization process, gene selection was performed considering a p value ≤ 0.05 and a fold change ± 2.0. Genes differentially expressed compared to the control vector (EV) are listed. Genes with fold change values ≥ 2.0 were considered as up-regulated, while those with fold change values ≤ -2.0 were considered as down-regulated (XLSX 90 kb)
705_2018_4124_MOESM5_ESM.xlsx (24 kb)
Supplementary Table S3. Genes modulated by the HPV18 E2-Af variant. After normalization process, gene selection was performed considering a p value ≤ 0.05 and a fold change ± 2.0. Genes differentially expressed compared to the control vector (EV) are listed. Genes with fold change values ≥ 2.0 were considered as up-regulated, while those with fold change values ≤ -2.0 were considered as down-regulated (XLSX 23 kb)
705_2018_4124_MOESM6_ESM.xlsx (16 kb)
Supplementary Table S4. Genes up-regulated and down-regulated by HPV18 E2-AsAi involved in death pathways. Analysis performed by the Ingenuity Pathway Analysis Tool shows that from a total of 100 genes associated to apoptotic pathways, 42 were found up-regulated and 58, down-regulated in E2-AsAi expressing cells (XLSX 15 kb)
705_2018_4124_MOESM7_ESM.xlsx (10 kb)
Supplementary Table S5. Genes up- and down-regulated by HPV18 E2-Af involved in death pathways. Analysis performed by the Ingenuity Pathway Analysis Tool showed 8 genes up-regulated and 8 down-regulated that are related to cellular death pathways in cells transfected with E2-Af variant (XLSX 10 kb)

References

  1. 1.
    de Sanjosé S, Brotons M, Pavón MA (2018) The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol 47:2–13.  https://doi.org/10.1016/J.BPOBGYN.2017.08.015 CrossRefGoogle Scholar
  2. 2.
    Bernard H-U (2005) The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 32:1–6.  https://doi.org/10.1016/J.JCV.2004.10.021 CrossRefGoogle Scholar
  3. 3.
    Bernard H-U, Calleja-Macias IE, Dunn ST (2006) Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 118:1071–1076.  https://doi.org/10.1002/ijc.21655 CrossRefGoogle Scholar
  4. 4.
    Burk RD, Terai M, Gravitt PE et al (2003) Distribution of human papillomavirus types 16 and 18 Variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 63:7215–7220Google Scholar
  5. 5.
    De la Cruz-Hernandez E (2005) Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J Gen Virol 86:2459–2468.  https://doi.org/10.1099/vir.0.80945-0 CrossRefGoogle Scholar
  6. 6.
    Lizano M, De la Cruz-Hernández E, Carrillo-García A et al (2006) Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol 102:230–235.  https://doi.org/10.1016/j.ygyno.2005.12.002 CrossRefGoogle Scholar
  7. 7.
    Lizano M, Berumen J, Guido MC et al (1997) Association between human papillomavirus type 18 variants and histopathology of cervical cancer. J Natl Cancer Inst 89:1227–1231.  https://doi.org/10.1093/jnci/89.16.1227 CrossRefGoogle Scholar
  8. 8.
    Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I et al (2009) E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 383:78–85.  https://doi.org/10.1016/j.virol.2008.09.040 CrossRefGoogle Scholar
  9. 9.
    McBride AA (2013) The Papillomavirus E2 proteins. Virology 445:57–79.  https://doi.org/10.1016/j.virol.2013.06.006 CrossRefGoogle Scholar
  10. 10.
    Pfefferle R, Marcuzzi GP, Akgül B et al (2008) The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 128:2310–2315.  https://doi.org/10.1038/JID.2008.73 CrossRefGoogle Scholar
  11. 11.
    Wu E-Q, Tang Y-Y (2014) Research progress in roles of high-risk human papillomavirus E2 protein. Chin J Virol 30:201–207Google Scholar
  12. 12.
    Graham SV (2016) Human papillomavirus E2 protein: linking replication, transcription, and RNA processing. J Virol 90:8384–8388.  https://doi.org/10.1128/JVI.00502-16 CrossRefGoogle Scholar
  13. 13.
    Muller M, Jacob Y, Jones L et al (2012) Large scale genotype comparison of human papillomavirus E2-host interaction networks provides new insights for E2 molecular functions. PLoS Pathog 8:e1002761.  https://doi.org/10.1371/journal.ppat.1002761 CrossRefGoogle Scholar
  14. 14.
    Muller M (2012) The HPV E2-host protein-protein interactions: a complex hijacking of the cellular network. Open Virol J 6:173–189.  https://doi.org/10.2174/1874357901206010173 CrossRefGoogle Scholar
  15. 15.
    Thierry F, Demeret C (2008) Direct activation of caspase 8 by the proapoptotic E2 protein of HPV18 independent of adaptor proteins. Cell Death Differ 15:1356–1363.  https://doi.org/10.1038/cdd.2008.53 CrossRefGoogle Scholar
  16. 16.
    Wang W, Fang Y, Sima N et al (2011) Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell lines is mediated by interaction with c-FLIP. Apoptosis 16:55–66.  https://doi.org/10.1007/s10495-010-0543-3 CrossRefGoogle Scholar
  17. 17.
    Blachon S, Demeret C (2003) The regulatory E2 proteins of human genital papillomaviruses are pro-apoptotic. Biochimie 85:813–819.  https://doi.org/10.1016/J.BIOCHI.2003.09.008 CrossRefGoogle Scholar
  18. 18.
    Hadaschik D, Hinterkeuser K, Oldak M et al (2003) The papillomavirus E2 protein binds to and synergizes with C/EBP factors involved in keratinocyte differentiation. J Virol 77:5253–5265.  https://doi.org/10.1128/JVI.77.9.5253 CrossRefGoogle Scholar
  19. 19.
    Jang MK, Anderson DE, van Doorslaer K, McBride AA (2015) A proteomic approach to discover and compare interacting partners of papillomavirus E2 proteins from diverse phylogenetic groups. Proteomics 15:2038–2050.  https://doi.org/10.1002/pmic.201400613 CrossRefGoogle Scholar
  20. 20.
    Schnabel C, Steger G, Schmidt H-M (2002) The hinge region of the human papillomavirus type 8 E2 protein activates the human p21WAF1/CIP1 promoter via interaction with Sp1. J Gen Virol 83:503–510.  https://doi.org/10.1099/0022-1317-83-3-503 CrossRefGoogle Scholar
  21. 21.
    Wang X, Naidu SR, Sverdrup F, Androphy EJ (2009) Tax1BP1 interacts with papillomavirus E2 and regulates E2-dependent transcription and stability. J Virol 83:2274–2284.  https://doi.org/10.1128/JVI.01791-08 CrossRefGoogle Scholar
  22. 22.
    Ramírez-Salazar E, Centeno F, Nieto K et al (2011) HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation. Virol J 8:247.  https://doi.org/10.1186/1743-422X-8-247 CrossRefGoogle Scholar
  23. 23.
    Sunthamala N, Pang CL, Thierry F et al (2014) Genome-wide analysis of high risk human papillomavirus E2 proteins in human primary keratinocytes. Genomics Data 2:147–149.  https://doi.org/10.1016/j.gdata.2014.06.013 CrossRefGoogle Scholar
  24. 24.
    López-Saavedra A, González-Maya L, Ponce-de-León S et al (2009) Functional implication of sequence variation in the long control region and E2 gene among human papillomavirus type 18 variants. Arch Virol 154:747–754.  https://doi.org/10.1007/s00705-009-0362-4 CrossRefGoogle Scholar
  25. 25.
    Yang YH, Speed T (2002) Design issues for cDNA microarray experiments. Nat Rev Genet 3:579–588.  https://doi.org/10.1038/nrg863 CrossRefGoogle Scholar
  26. 26.
    Wang J, Vasaikar S, Shi Z et al (2017) WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45:W130–W137.  https://doi.org/10.1093/nar/gkx356 CrossRefGoogle Scholar
  27. 27.
    Demeret C, Garcia-Carranca A, Thierry F (2003) Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 22:168–175.  https://doi.org/10.1038/sj.onc.1206108 CrossRefGoogle Scholar
  28. 28.
    Lai D, Tan CL, Gunaratne J et al (2013) Localization of HPV-18 E2 at mitochondrial membranes induces ROS release and modulates host cell metabolism. PLoS One 8:e75625.  https://doi.org/10.1371/journal.pone.0075625 CrossRefGoogle Scholar
  29. 29.
    Webster K, Parish J, Pandya M et al (2000) The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275:87–94.  https://doi.org/10.1074/jbc.275.1.87 CrossRefGoogle Scholar
  30. 30.
    Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–560.  https://doi.org/10.1038/nrc2886 CrossRefGoogle Scholar
  31. 31.
    Bellanger S, Tan CL, Xue YZ et al (2011) Tumor suppressor or oncogene? A critical role of the human papillomavirus (HPV) E2 protein in cervical cancer progression. Am J Cancer Res 1:373–389Google Scholar
  32. 32.
    Krüppel U, Müller-Schiffmann A, Baldus SE et al (2008) E2 and the co-activator p300 can cooperate in activation of the human papillomavirus type 16 early promoter. Virology 377:151–159.  https://doi.org/10.1016/j.virol.2008.04.006 CrossRefGoogle Scholar
  33. 33.
    Lizano M, Berumen J, García-Carrancá A (2009) HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res 40:428–434.  https://doi.org/10.1016/j.arcmed.2009.06.001 CrossRefGoogle Scholar
  34. 34.
    Lavezzo E, Masi G, Toppo S et al (2016) Characterization of intra-type variants of oncogenic human papillomaviruses by next-generation deep sequencing of the E6/E7 region. Viruses 8:79.  https://doi.org/10.3390/v8030079 CrossRefGoogle Scholar
  35. 35.
    Nicolás-Párraga S, Alemany L, de Sanjosé S et al (2017) Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. Int J Cancer 140:2092–2100.  https://doi.org/10.1002/ijc.30636 CrossRefGoogle Scholar
  36. 36.
    Tornesello ML, Losito S, Benincasa G et al (2011) Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 121:32–42.  https://doi.org/10.1016/j.ygyno.2010.12.005 CrossRefGoogle Scholar
  37. 37.
    Zhang L, Yang B, Zhang A et al (2016) Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization. J Med Virol 88:1982–1988.  https://doi.org/10.1002/jmv.24541 CrossRefGoogle Scholar
  38. 38.
    Zhang L, Liao H, Yang B et al (2015) Variants of human papillomavirus type 16 predispose toward persistent infection. Int J Clin Exp Pathol 8:8453–8459Google Scholar
  39. 39.
    Hochmann J, Sobrinho JS, Villa LL, Sichero L (2016) The Asian-American variant of human papillomavirus type 16 exhibits higher activation of MAPK and PI3K/AKT signaling pathways, transformation, migration and invasion of primary human keratinocytes. Virology 492:145–154.  https://doi.org/10.1016/j.virol.2016.02.015 CrossRefGoogle Scholar
  40. 40.
    Togtema M, Jackson R, Richard C et al (2015) The human papillomavirus 16 European-T350G E6 variant can immortalize but not transform keratinocytes in the absence of E7. Virology 485:274–282.  https://doi.org/10.1016/j.virol.2015.07.025 CrossRefGoogle Scholar
  41. 41.
    Zacapala-Gómez AE, Del Moral-Hernández O, Villegas-Sepúlveda N et al (2016) Changes in global gene expression profiles induced by HPV 16 E6 oncoprotein variants in cervical carcinoma C33-A cells. Virology 488:187–195.  https://doi.org/10.1016/j.virol.2015.11.017 CrossRefGoogle Scholar
  42. 42.
    Ekalaksananan T, Jungpol W, Prasitthimay C et al (2014) Polymorphisms and functional analysis of the intact human papillomavirus 16 E2 gene. Asian Pacific J Cancer Prev 15:10255–10262.  https://doi.org/10.7314/APJCP.2014.15.23.10255 CrossRefGoogle Scholar
  43. 43.
    Hang D, Gao L, Sun M et al (2014) Functional effects of sequence variations in the E6 and E2 genes of human papillomavirus 16 European and Asian variants. J Med Virol 86:618–626.  https://doi.org/10.1002/jmv.23792 CrossRefGoogle Scholar
  44. 44.
    Parish JL, Kowalczyk A, Chen H-T et al (2006) E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J Virol 80:4580–4590.  https://doi.org/10.1128/JVI.80.9.4580-4590.2006 CrossRefGoogle Scholar
  45. 45.
    Massimi P, Pim D, Bertoli C et al (1999) Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18:7748–7754.  https://doi.org/10.1038/sj.onc.1203208 CrossRefGoogle Scholar
  46. 46.
    Crook T, Wrede D, Vousden KH (1991) p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873–875Google Scholar
  47. 47.
    Kazemi S, Papadopoulou S, Li S et al (2004) Control of subunit of eukaryotic translation initiation factor 2 (eIF2) Phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2-dependent gene expression and cell death. Mol Cell Biol 24:3415–3429.  https://doi.org/10.1128/MCB.24.8.3415-3429.2004 CrossRefGoogle Scholar
  48. 48.
    Bermudez-Morales VH, Peralta-Zaragoza O, Guzman-Olea E et al (2009) HPV 16 E2 protein induces apoptosis in human and murine HPV 16 transformed epithelial cells and has antitumoral effects in vivo. Tumor Biol 30:61–72.  https://doi.org/10.1159/000214438 CrossRefGoogle Scholar
  49. 49.
    Prabhavathy D, Prabhakar BN, Karunagaran D (2014) HPV16 E2-mediated potentiation of NF-κB activation induced by TNF-α involves parallel activation of STAT3 with a reduction in E2-induced apoptosis. Mol Cell Biochem 394:77–90.  https://doi.org/10.1007/s11010-014-2083-6 CrossRefGoogle Scholar
  50. 50.
    Singh N, Senapati S, Bose K (2016) Insights into the mechanism of human papillomavirus E2-induced procaspase-8 activation and cell death. Sci Rep 6:21408.  https://doi.org/10.1038/srep21408 CrossRefGoogle Scholar
  51. 51.
    Tzeng H-T, Wang Y-C (2016) Rab-mediated vesicle trafficking in cancer. J Biomed Sci 23:70.  https://doi.org/10.1186/s12929-016-0287-7 CrossRefGoogle Scholar
  52. 52.
    Gross A (2016) BCL-2 family proteins as regulators of mitochondria metabolism. Biochim Biophys Acta Bioenerg 1857:1243–1246.  https://doi.org/10.1016/j.bbabio.2016.01.017 CrossRefGoogle Scholar
  53. 53.
    Patergnani S, Marchi S, Rimessi A et al (2013) PRKCB/protein kinase C, beta and the mitochondrial axis as key regulators of autophagy. Autophagy 9:1367–1385.  https://doi.org/10.4161/auto.25239 CrossRefGoogle Scholar
  54. 54.
    Sheren JE, Kassenbrock CK (2013) RNF38 encodes a nuclear ubiquitin protein ligase that modifies p53. Biochem Biophys Res Commun 440:473–478.  https://doi.org/10.1016/j.bbrc.2013.08.031 CrossRefGoogle Scholar
  55. 55.
    Seachrist JL, Ferguson SS (2003) Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci 74:225–235.  https://doi.org/10.1016/J.LFS.2003.09.009 CrossRefGoogle Scholar
  56. 56.
    Yang H-J, Wang M, Wang L et al (2015) NF-κB regulates caspase-4 expression and sensitizes neuroblastoma cells to Fas-induced apoptosis. PLoS One 10:e0117953.  https://doi.org/10.1371/journal.pone.0117953 CrossRefGoogle Scholar
  57. 57.
    Lazzari E, Jefferies CA (2014) IRF5-mediated signaling and implications for SLE. Clin Immunol 153:343–352.  https://doi.org/10.1016/j.clim.2014.06.001 CrossRefGoogle Scholar
  58. 58.
    Alsamman K, El-Masry OS (2018) Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 38:BSR20171672.  https://doi.org/10.1042/bsr20171672
  59. 59.
    Doorbar J, Egawa N, Griffin H et al (2015) Human papillomavirus molecular biology and disease association. Rev Med Virol 25:2–23.  https://doi.org/10.1002/rmv.1822 CrossRefGoogle Scholar
  60. 60.
    Barber GN (2001) Host defense, viruses and apoptosis. Cell Death Differ 8:113–126.  https://doi.org/10.1038/sj.cdd.4400823 CrossRefGoogle Scholar
  61. 61.
    Fuentes-González A, Contreras-Paredes A, Manzo-Merino J, Lizano M (2013) The modulation of apoptosis by oncogenic viruses. Virol J 10:182.  https://doi.org/10.1186/1743-422X-10-182 CrossRefGoogle Scholar
  62. 62.
    Cai Q, Lv L, Shao Q et al (2013) Human papillomavirus early proteins and apoptosis. Arch Gynecol Obstet 287:541–548.  https://doi.org/10.1007/s00404-012-2665-z CrossRefGoogle Scholar
  63. 63.
    Yuan C-H, Filippova M, Duerksen-Hughes P (2012) Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses 4:3831–3850.  https://doi.org/10.3390/v4123831 CrossRefGoogle Scholar
  64. 64.
    Manzo-Merino J, Massimi P, Lizano M, Banks L (2014) The human papillomavirus (HPV) E6 oncoproteins promotes nuclear localization of active caspase 8. Virology 450–451:146–152.  https://doi.org/10.1016/j.virol.2013.12.013 CrossRefGoogle Scholar
  65. 65.
    Bernard X, Robinson P, Nominé Y et al (2011) Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One 6:e25981.  https://doi.org/10.1371/journal.pone.0025981 CrossRefGoogle Scholar
  66. 66.
    DeFilippis RA, Goodwin EC, Wu L, DiMaio D (2003) Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 77:1551–1563.  https://doi.org/10.1128/JVI.77.2.1551-1563.2003 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019
corrected publication 2019

Authors and Affiliations

  • Alma Mariana Fuentes-González
    • 1
    • 2
  • J. Omar Muñoz-Bello
    • 1
    • 2
  • Joaquín Manzo-Merino
    • 3
  • Adriana Contreras-Paredes
    • 2
  • Abraham Pedroza-Torres
    • 3
  • Jorge Fernández-Retana
    • 2
  • Carlos Pérez-Plasencia
    • 2
  • Marcela Lizano
    • 2
    • 4
    Email author
  1. 1.Programa de Doctorado en Ciencias BiomédicasUniversidad Nacional Autónoma de México, Ciudad UniversitariaMexico CityMexico
  2. 2.Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, México/Instituto de Investigaciones BiomédicasUniversidad Nacional Autónoma de MéxicoMexico CityMexico
  3. 3.CONACyT-Instituto Nacional de CancerologíaMexico CityMexico
  4. 4.Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones BiomédicasUniversidad Nacional Autónoma de MéxicoMexico CityMexico

Personalised recommendations